americanpharmaceuticalreviewMarch 14, 2017
Tag: FORMA
FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, has announced the achievement of a clinical development milestone in their alliance with Boehringer Ingelheim (BI). The partnership focuses on the discovery and development of novel drug candidates against protein-protein interactions for the treatment of cancer. Financial milestones payable to FORMA for this achievement have not been disclosed.
"FORMA’s discovery and early clinical development successes, across our wholly-owned pipeline as well as programs in collaboration with pharmaceutical partners, accentuates the value of a unique compound collection and productivity of talented teams across collaborative networks" said John Hohneker, M.D., EVP and Head of Research and Development at FORMA. "We are pleased to see tractable progress of protein-protein modulators and to have contributed to BI’s clinical candidate pipeline, enabled by the collective grit of R&D teams, boldly and courageously taking on such challenging programs."
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: